很多仿制药公司现在大概正忙着推出与立普妥的非专利药,价格仅为立普妥的1/5。
Patients and health-care payers should reap the benefit.
病人和医疗费用支付方会收益,而辉瑞的收入会缩水。
Pfizer s revenues should suffer. The same story will be repeated many times, as otherbest-selling drugs march over the patent cliff .
同样的事件将反复上演,因为其他畅销药也要临近 专利悬崖 。
But generics makers may face delays getting their cheaper versions to market.
然而,非专利制药企业却发现仿制药上市一拖再拖。
Ranbaxy, a Japanese-owned drugmaker, struggled to get regulators approval for itsgeneric version of Lipitor, and only won it on the day the patent expired.
兰伯西这家日本制药企业历尽艰辛,获得了立普妥非专利药的生产许可,但该许可要到专利失效那天才生效。
More important, research-based drug firms are using a variety of tactics to make the patentcliff slope more gently.
更重要的是,以研发为基础的制药公司正使用各种方法缓冲 专利悬崖 效应。
Jon Leibowitz, chairman of America s Federal Trade Commission , is concerned bydrugmakers filing frivolous additional patents on their products to put off the day whentheir protection expires.
【2015考研英语阅读制药企业悬念】相关文章:
最新
2016-10-18
2016-10-11
2016-10-11
2016-10-08
2016-09-30
2016-09-30